ZYME (Zymeworks) Cyclically Adjusted Revenue per Share: $1.91 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYME Zymeworks Inc ZYME
67 GF Score
Price $24.20
GF Value $26.03
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks Cyclically Adjusted Revenue per Share?

Zymeworks ZYME 67 Cyclically Adjusted Revenue per Share is $1.91 as of Mar. 2026. GuruFocus rates ZYME with a GF Score™ of 67/100 and a GF Value™ of $26.03 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zymeworks's adjusted revenue per share for the three months ended in Mar. 2026 was $0.032. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.91 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-17), Zymeworks's current stock price is $24.20. Zymeworks's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.91. Zymeworks's Cyclically Adjusted PS Ratio of today is 12.67.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zymeworks was 14.71. The lowest was 8.57. And the median was 12.54.


Zymeworks  (NAS:ZYME) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zymeworks's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.20/1.91
=12.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zymeworks was 14.71. The lowest was 8.57. And the median was 12.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zymeworks Cyclically Adjusted Revenue per Share Related Terms


Zymeworks Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zymeworks's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks Cyclically Adjusted Revenue per Share Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.87

Zymeworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.92 1.87 1.91

ZYME vs SRPT, BCAX, INVA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zymeworks's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cyclically Adjusted PS Ratio falls into.


ZYME
67GF Score
Zymeworks Inc ZYME
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zymeworks's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.032/330.2130*330.2130
=0.032

Current CPI (Mar. 2026) = 330.2130.

Zymeworks Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.320 241.018 0.438
201609 0.109 241.428 0.149
201612 0.113 241.432 0.155
201703 0.012 243.801 0.016
201706 0.064 244.955 0.086
201709 0.005 246.819 0.007
201712 1.969 246.524 2.637
201803 0.002 249.554 0.003
201806 0.819 251.989 1.073
201809 0.064 252.439 0.084
201812 0.904 251.233 1.188
201903 0.372 254.202 0.483
201906 0.240 256.143 0.309
201909 0.181 256.759 0.233
201912 0.043 256.974 0.055
202003 0.170 258.115 0.217
202006 0.243 257.797 0.311
202009 0.052 260.280 0.066
202012 0.307 260.474 0.389
202103 0.013 264.877 0.016
202106 0.034 271.696 0.041
202109 0.084 274.310 0.101
202112 0.381 278.802 0.451
202203 0.031 287.504 0.036
202206 0.082 296.311 0.091
202209 0.040 296.808 0.045
202212 6.032 296.797 6.711
202303 0.533 301.836 0.583
202306 0.104 305.109 0.113
202309 0.234 307.789 0.251
202312 0.239 306.746 0.257
202403 0.132 312.332 0.140
202406 0.252 314.175 0.265
202409 0.210 315.301 0.220
202412 0.415 315.605 0.434
202503 0.360 319.799 0.372
202506 0.630 322.561 0.645
202509 0.364 324.800 0.370
202512 0.033 324.054 0.034
202603 0.032 330.213 0.032

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.91 mean?
Zymeworks (ZYME) has a Cyclically Adjusted Revenue per Share of $1.91 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zymeworks and its competitors.
Is Zymeworks' Cyclically Adjusted Revenue per Share too high?
Zymeworks' current Cyclically Adjusted Revenue per Share is $1.91. Overall, Zymeworks has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Cyclically Adjusted Revenue per Share compare to SRPT and BCAX?
Zymeworks' Cyclically Adjusted Revenue per Share of $1.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zymeworks and its competitors. Zymeworks's current Cyclically Adjusted Revenue per Share is $1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $26.03, compared to a current price of $24.20 — trading 7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.91. Zymeworks' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zymeworks (ZYME), the current Cyclically Adjusted Revenue per Share is $1.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be undervalued. The current stock price of $24.20 is trading 7% below its estimated GF Value™ of $26.03. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Cyclically Adjusted Revenue per Share: $1.91
  • GF Value™: $26.03 vs. price of $24.20 (7% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
67GF Score

Get the complete analysis for ZYME

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.20
Price
$26.03
GF Value